Author: Andrew Celentano - Page 4 - Start Medical Product Development

Immune system protein is a cancer killer on its own, new study shows

October 29, 2026

For decades, scientists have known that a protein made by T cells and natural killer (NK) cells in the immune system, called perforin, can kill tumor cells by punching a hole in the cell wall and injecting proteases called granzymes, which kill the cell. Now, new work led by researchers at the University of Michigan Health Rogel Cancer Center found that tumor cells could be killed even when major granzymes were missing.

A soft robot could help doctors diagnose and treat disorders of the small intestine

October 28, 2026

MIT engineers designed a robotic enteroscope that can inch through the hard-to-reach small intestine, making biopsies and drug delivery easier.

Capturing the complete process of embryonic development

October 28, 2026

By tracking over 1 million cells, researchers created a detailed map of embryonic development in mice. It could provide development and disease insights.

Empatica launches WellPD, an FDA-cleared Parkinson’s monitoring device for home use

October 28, 2026

BOSTON, Oct. 28, 2026 /PRNewswire/ — Empatica, a leader in digital biomarker development and clinical-grade wearable technology, today announced WellPD, an FDA-cleared and CE-marked wearable device and companion app for people with Parkinson’s to monitor their symptoms at home.

FDA clears Deep Reasoning AI’s NeuroDR for neurovascular CT scans

October 28, 2026

The clearance was secured 105 days after submission, with Deep Reasoning AI now planning to supply the platform in the US.

Pharaoh Neuro’s CSF filtration system wins FDA breakthrough designation

October 28, 2026

Pharaoh Neuro’s minimally invasive system for filtering cerebrospinal fluid has received a breakthrough designation from the FDA, with its design to clean out unwanted blood following certain internal brain bleeds

FDA approves Abbott’s new Amplatzer occluder for paravalvular leaks

October 28, 2026

Abbott (NYSE: ABT) has secured an FDA approval for a minimally invasive system to plug new leaks in a replacement heart valve, without requiring the patient to undergo open surgery a second time.

Preclinical research shows macrophages can be programmed to fight solid cancer tumors

October 28, 2026

One person dies every 50 seconds in the U.S. from cancer, and an estimated 39% of people in the country will develop cancer during their lifetime. Survival rates have improved in recent decades from innovations and combinations of treatments, including surgery, chemotherapy, radiation, immunotherapy and biotechnology. Still, some cancers resist treatment or recur.

Lab-on-a-chip predicts which cancer treatments may work for pediatric acute lymphoblastic leukemia

October 28, 2026

More than 120,000 people in the U.S. are living with acute lymphoblastic leukemia (ALL), and 6,000 new cases are diagnosed each year. Of those, more than 3,500 will be in children. Responsible for 75% of all pediatric leukemia diagnoses, ALL is a rapid-onset blood cancer, preventing the body from producing mature, infection-fighting white blood cells, sometimes within a matter of months.

3D-printed implant prototype combines brain activity recording with targeted cooling

October 27, 2026

Researchers affiliated with the Leibniz Institute of Polymer Research Dresden (IPF) and the Else Kröner Fresenius Center (EKFZ) for Digital Health at TU Dresden have developed a 3D-printed implant prototype that combines the recording of brain activity with targeted cooling. The technology could pave the way for alternative approaches to treating drug-resistant focal epilepsy. The research is published in the journal Advanced Science.